KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Financing Activities: 2017-2025

Historic Cash from Financing Activities for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $81.4 million.

  • Aquestive Therapeutics' Cash from Financing Activities rose 478988.24% to $81.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.1 million, marking a year-over-year increase of 16.90%. This contributed to the annual value of $83.6 million for FY2024, which is 2003.47% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Cash from Financing Activities stood at $81.4 million, which was up 81,511.00% from -$100,000 recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Cash from Financing Activities peaked at $81.7 million during Q1 2024, and registered a low of -$9.2 million during Q1 2023.
  • Its 3-year average for Cash from Financing Activities is $17.2 million, with a median of $3.9 million in 2023.
  • As far as peak fluctuations go, Aquestive Therapeutics' Cash from Financing Activities tumbled by 809.17% in 2023, and later surged by 478,988.24% in 2025.
  • Over the past 5 years, Aquestive Therapeutics' Cash from Financing Activities (MRQ) stood at $5.5 million in 2021, then plummeted by 95.71% to $234,000 in 2022, then soared by 1,572.22% to $3.9 million in 2023, then plummeted by 95.99% to $157,000 in 2024, then skyrocketed by 51,754.14% to $81.4 million in 2025.
  • Its Cash from Financing Activities was $81.4 million in Q3 2025, compared to -$100,000 in Q2 2025 and $20.6 million in Q1 2025.